CU Bancorp (NASDAQ:CUNB) shares increased 2.21% in last trading session and ended the day at $24.48. CUNB has a return on assets of 0.60%. CU Bancorp (NASDAQ:CUNB) quarterly performance is 10.87%.
CU Bancorp (NASDAQ:CUNB) reported financial results for the third quarter of 2015. Net income for the third quarter of 2015 was $6.3 million and net income available to common shareholders was $6.0 million or $0.35 per fully diluted share, compared with net income of $2.5 million or $0.23 per fully diluted share for the third quarter of 2014.
Dun & Bradstreet Corp. (NYSE:DNB) ended the last trading day at $111.02. Company weekly volatility is calculated as 1.79% and price to cash ratio as 29.09. Dun & Bradstreet Corp. (NYSE:DNB) showed a weekly performance of -2.00%.
Dun & Bradstreet Corp. (NYSE:DNB) declared a cash dividend of $0.4625 on Oct 21, 2015. The shares will quote ex-dividend on Nov 23, 2015 and the record date has been fixed on Nov 25, 2015. At Oct 21, 2015 share price, the yield comes out to be 1.6331%. The dividend payable date has been fixed on Dec 11, 2015.
On 27 October, Philippine Long Distance Telephone (ADR) (NYSE:PHI) shares decreased -3.46% and was closed at $49.16. PHI EPS growth in last 5 year was -3.13%. Philippine Long Distance Telephone (ADR) (NYSE:PHI) year to date (YTD) performance is -17.97%.
Philippine Long Distance Telephone (ADR) (NYSE:PHI) was upgraded by Zacks from a “sell” rating to a “hold” rating in a research note issued to investors on Tuesday, MarketBeat reports.
Chimerix, Inc. (NASDAQ:CMRX) shares increased 5.26% in last trading session and ended the day at $37.81. CMRX has a return on assets of -28.50%. Chimerix, Inc. (NASDAQ:CMRX) quarterly performance is -28.24%.
On 22 October, Chimerix, Inc. (NASDAQ:CMRX) announced initiation of dosing in SURPASS one of the two Phase 3 trials in the brincidofovir kidney transplant program. Both the SUSTAIN and SURPASS trials are evaluating brincidofovir for the prevention of cytomegalovirus (CMV) disease in kidney transplant recipients; both trials are now actively enrolling.
Gilead Sciences Inc. (NASDAQ:GILD) caters to the Healthcare space. It has a net profit margin of 51.50% and weekly performance is 9.15%. On the last day of trading company shares ended up at $110.96. Gilead Sciences Inc. (NASDAQ:GILD) distance from 50-day simple moving average (SMA50) is 6.42%.
Gilead Sciences Inc. (NASDAQ:GILD) announced its results of operations for the third quarter ended September 30, 2015. The financial results that follow represent a year-over-year comparison of third quarter 2015 to the third quarter 2014. Total revenues were $8.3 billion in 2015 compared to $6.0 billion in 2014. Net income was $4.6 billion or $3.06 per diluted share in 2015 compared to $2.7 billion or $1.67 per diluted share in 2014.
Leave a Reply